GSTM1 Tissue Genotype as a Recurrence Predictor in Nonmuscle Invasive Bladder Cancer

다국어 초록 (Multilingual Abstract)

Tissue genotyping is more useful approach than using blood genomic DNA, which can reflect the effects of the somatic mutations in cancer. Although polymorphisms in glutathione S-transferase (GST ) have been associated with the risk of bladder cancer (BC)development, few reports provide information about the prognosis of BC. We investigated glutathione S-transferase mu (GSTM1) and glutathione S-transferase theta (GSTT1)genotypes using genomic DNA from primary 165 BC tissue samples to assess the association with disease prognosis. DNA samples from tumor were analyzed by multiplex polymerase chain reaction (PCR). The results were compared with clinicopathological parameters. The prognostic significance of the GSTs was evaluated by Kaplan-Meier and multivariate Cox regression model. Kaplan-Meier estimates revealed significant differences in time to tumor recurrence according to the GSTM1 tissue genotype (P = 0.038) in nonmuscle invasive bladder cancer (NMIBC). Multivariate Cox regression analysis also revealed that the tissue GSTM1 genotype (hazards ratio [HR]: 0.377, P = 0.031) was an independent predictor of bladder tumor recurrence in NMIBC. This identification of GSTM1tissue genotype as a prognosticator for determining recurrence in NMIBC should prove highly useful in a clinical setting.

참고문헌 (Reference)

1 Grossman HB, "p53 and RB expression predict progression in T1 bladder cancer" 4 : 829-834, 1998

2 하윤석, "mRNA Expression of S100A8 as a Prognostic Marker for Progression of Non-Muscle-Invasive Bladder Cancer" 대한비뇨기과학회 51 (51): 15-20, 2010

3 Wu XR, "Urothelial tumorigenesis: a tale of divergent pathways" 5 : 713-725, 2005

4 Stenzl A, "The updated EAU guidelines on muscle- invasive and metastatic bladder cancer" 55 : 815-825, 2009

5 Botteman MF, "The health economics of bladder cancer: a comprehensive review of the published literature" 21 : 1315-1330, 2003

6 van Rhijn BW, "The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate" 61 : 1265-1268, 2001

7 Divrik RT, "The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial" 175 : 1641-1644, 2006

8 Greene FL, "The American Joint Committee on Cancer: updating the strategies in cancer staging" 87 : 13-15, 2002

9 Thalmann GN, "Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy" 172 : 70-75, 2004

10 Kim WJ, "Predictive value of progressionrelated gene classifier in primary non-muscle invasive bladder cancer" 9 : 3-, 2010

11 Pfister C, "Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence" 5 : 4079-4084, 1999

12 Kim WJ, "Polymorphisms of N-acetyltransferase 2, glutathione S-transferase mu and theta genes as risk factors of bladder cancer in relation to asthma and tuberculosis" 164 : 209-213, 2000

13 Kim EJ, "Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor" LIPPINCOTT WILLIAMS & WILKINS 180 : 1141-1145, 2008

14 Chen H, "Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect" 347 : 295-297, 1996

15 Mostofi FK, "Histological typing of urinary bladder tumors. International Histologic Classification of Tumors" World Health Organzation 1973

16 Hall MC, "Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update" 178 : 2314-2330, 2007

17 Bell DA, "Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer" 85 : 1159-1164, 1993

18 Kim YJ, "Gene Signatures for the Prediction of Response to Bacillus Calmette-Guerin Immunotherapy in Primary pT1 Bladder Cancers" AMER ASSOC CANCER RESEARCH 16 (16): 2131-2137, 2010

19 Ha YS, "GSTT1: A marker of the aggressiveness of bladder cancer" KARGER 86 (86): 41-46, 2011

20 김헌, "GSTT1-null genotype is a protective factor against bladder cancer" 60 (60): 913-918, 200211

21 김태환, "Forkhead box O-class 1 and Forkhead box G1 as Prognostic Markers for Bladder Cancer" 대한의학회 24 (24): 468-473, 2009

22 Babjuk M, "European Association of Urology (EAU). EAU guidelines on nonmuscle- invasive urothelial carcinoma of the bladder" 54 : 303-314, 2008

23 Hirao Y, "Environmental factors promoting bladder cancer" LIPPINCOTT WILLIAMS & WILKINS 19 (19): 494-499, 2009

24 Guey LT, "EPICURO/Spanish Bladder Cancer Study investigators. Genetic susceptibility to distinct bladder cancer subphenotypes" 57 : 283-292, 2010

25 Shariat SF, "Concomitant carcinoma in situ is a feature of aggressive disease in patients with organconfined TCC at radical cystectomy" 51 : 152-160, 2007

26 Brockmöller J, "Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione Stransferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk" 56 : 3915-3925, 1996

27 Borden LS Jr, "Bladder cancer" 15 : 227-233, 2003

28 Srivastava DS, "Association of genetic polymorphism of glutathione S-transferase M1, T1, P1 and susceptibility to bladder cancer" 48 : 339-344, 2005

29 Song DK, "Association of NAT2, GSTM1, GSTT1, CYP2A6, and CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in Central China" 32 : 416-423, 2009

30 Ramani VA, "A contemporary standard for morbidity and outcome after radical cystectomy" 104 : 628-632, 2009